European Specialty Pharmaceutical Company Launches First Products in UK
Neuraxpharm Group has announced it is launching its first products in the United Kingdom.
European specialty pharmaceutical company focused on the treatment of the central nervous system (CNS), Neuraxpharm Group, has announced it is launching its first products in the United Kingdom, in a July 31, 2019 press release.
The company plans to launch differentiated and specialty generics within the UK, which comprises 11% of the European market in terms of CNS pharmaceuticals. In addition to launching products, the company has appointed a general manager (Craig Bowen) to run the UK arm of the business, which will be based in Reading, UK.
“Establishing a strong presence in the UK will enable us to build on our position as a CNS specialist in Europe offering consumer healthcare products, standard generics, and added value medicines,” said Jörg-Thomas Dierks, CEO of Neuraxpharm in the press release. “We are very pleased to welcome Craig to the Neuraxpharm team. His proven track record of launching new pharmaceutical products will be of great advantage in bringing differentiated products to local patients and healthcare professionals in the UK, one of the top five markets in Europe.”
Source: Neuraxpharm
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
INTERPHEX 2025: Use of Walk-In Chambers for Bio/Pharma Development and Manufacturing
April 2nd 2025Sitting down with the PharmTech Group at INTERPHEX 2025, Christopher Murphy, director of Global Business Development and Service Customer Support at Environmental Specialties, discusses the design and critical role of walk-in chambers in the bio/pharmaceutical industry.
